$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

[해외논문] Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when? 원문보기

Journal of hepatology : the journal of the European Association for the Study of the Liver, v.33 no.2, 2000년, pp.329 - 332  

Fontana, R.J. ,  Lok, A.S.F.

초록이 없습니다.

참고문헌 (35)

  1. Semin Liver Dis Margolis 11 84 1991 10.1055/s-2008-1040427 Hepatitis B: evolving epidemiology and implications for control 

  2. Clin Microbiol Rev Mahoney 12 351 1999 10.1128/CMR.12.2.351 Update on diagnosis, management, and prevention of hepatitis B virus infection 

  3. Br J Surg Pugh 60 646 1973 10.1002/bjs.1800600817 Transection of the esophagus for bleeding esophageal varices 

  4. Hepatology Christensen 4 430 1984 10.1002/hep.1840040313 Prognostic value of Child-Turcotte cirteria in medically treated cirrhosis 

  5. Ann Intern Med Weissberg 101 613 1984 10.7326/0003-4819-101-5-613 Survival in chronic hepatitis B. An analysis of 379 patients 

  6. Gastroenterology de Jongh 103 1630 1992 10.1016/0016-5085(92)91188-A Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver 

  7. Hepatology Donato 26 579 1997 10.1002/hep.510260308 Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy 

  8. J Infect Dis Fattovich 155 931 1987 10.1093/infdis/155.5.931 Influence of hepatitis Delta virus infection on progression to cirrhosis in chronic hepatitis B 

  9. J Hepatol Realdi 21 656 1994 10.1016/S0168-8278(94)80115-0 Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis 

  10. Hepatology Liaw 13 627 1991 10.1002/hep.1840130403 Incidence, determinants, and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study 

  11. N Engl J Med Lee 337 1733 1997 10.1056/NEJM199712113372406 Hepatitis B virus infection 

  12. N Engl J Med Dienstag 341 1256 1999 10.1056/NEJM199910213411702 Lamivudine as initial treatment for chronic hepatitis B in the United States 

  13. N Engl J Med Lai 339 61 1998 10.1056/NEJM199807093390201 A one year trial of lamivudine for chronic hepatitis B 

  14. Gastroenterolgy Perrillo 109 908 1995 10.1016/0016-5085(95)90401-8 Low dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus 

  15. Gastroenterology Hoofnagle 104 1116 1993 10.1016/0016-5085(93)90281-G Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B 

  16. Hepatology Tassopoulos 29 889 1999 10.1002/hep.510290321 Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA positive (Precore mutant) chronic hepatitis B 

  17. Hepatology Schiff 28 388A 1998 A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy 

  18. Hepatology Villeneuve 31 207 2000 10.1002/hep.510310130 Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B 

  19. Hepatology Perrillo 30 301A 1999 Lamivudine for suppression of viral replication in patients with decompensated chronic hepatitis B 

  20. J Hepatol Yao 33 301 2000 10.1016/S0168-8278(00)80371-2 Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection 

  21. J Hepatol Kapoor 33 308 2000 10.1016/S0168-8278(00)80372-4 Beneficial effects of lamivudine in hepatitis B virus related decompensated cirrhosis 

  22. Transplantation Fontana 67 S16 1999 10.1097/00007890-199904150-00068 Is lamivudine beneficial in HBsAg+ patients awaiting liver transplantation? Experience in 182 North American patients 

  23. J Hepatol Leung 30 Suppl 1 59 1999 Three year lamivudine therapy in chronic HBV 

  24. Antiviral Therapy Chang 5 Suppl. 1 44 2000 Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV patients treated with lamivudine for four years 

  25. Hepatology Melegari 27 628 1998 10.1002/hep.510270243 Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective 

  26. J Hepatol Honkoop 26 1393 1997 10.1016/S0168-8278(97)80476-X Lamivudine resistance in immunocompetent chronic hepatitis B 

  27. Lancet Bartholomew 349 20 1998 10.1016/S0140-6736(96)02266-0 Hepatitis-B-virus resistance to lamvudine given for recurrent infection after orthotopic liver transplantation 

  28. Hepatology Liaw 30 567 1999 10.1002/hep.510300221 Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamvudine therapy 

  29. J Hepatol Mutimer 30 715 1999 10.1016/S0168-8278(99)80204-9 High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation 

  30. J Infect Dis Mutimer 181 713 2000 10.1086/315238 Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy 

  31. J Hepatol de Man 29 669 1998 10.1016/S0168-8278(98)80164-5 The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famiciclovir non-response, followed by lamivudine resistance resulting in graft loss 

  32. Hepatology Xiong 28 1669 1998 10.1002/hep.510280629 Mutations in hepatitis B DNA polymerase with resistance to lamvudine do not confer resistance to adefovir in vitro 

  33. Gastroenterology Perrillo 116 L0356 1999 In vivo demonstration of sensitivity of YMDD mutants to adefovir 

  34. J Infect Dis Gauthier 180 1757 1999 10.1086/315147 Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine 

  35. Hepatology Perrillo 29 1581 1999 10.1002/hep.510290507 Multicenter study of lamivudine therapy for hepatitis B after liver transplantation 

관련 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로